Gaithersburg, Md.– June 4, 2015 — VLP Therapeutics, LLC. (“VLP”), a Gaithersburg-based biotechnology company focusing on the research and development of therapeutic and preventative vaccines and next generation antibody agents based upon a novel and proprietary vaccine technology, announced that it has initiated a research collaboration with the National Cancer Center’s National Cancer Center Research Institute in Japan. The collaboration will help facilitate VLP’s research and development of cancer vaccine candidates.

“We are very excited with the partnership with the National Cancer Center (“NCC”) in Japan. Our work with the NCC will facilitate the key proof of concept studies to evaluate the potential efficacy of our i-alpha VLP Technology-based cancer vaccine candidates” said Dr. Wataru Akahata, Ph.D., Co-Founder and Chief Executive Officer of VLP. “Cancer is one of our key strategic focuses. We are evaluating the application of i-alpha VLP Technology both as a therapeutic vaccine and molecular targeted therapy for this indication. Through this collaboration, we will be able to establish the first proof of concept of our candidates in cancer and, if successful, move forward with the program and potential partnership” Dr. Akahata continued.

About VLP Therapeutics

VLP was established in 2012 by a group of seasoned entrepreneurs based upon a novel, proprietary vaccine technology discovered by its co-founder Dr. Akahata. Its vision is to combat the 21st century global public health problems through revolutionary i-alpha VLP Technology, and the mission is to develop innovative medical treatment which transforms traditional vaccine and targeted antibody therapies to address global unmet medical needs. VLP is currently developing preventative and therapeutic vaccines as well as next generation of targeted antibody agents to treat cancer, infectious diseases, auto-immune diseases and neurological diseases.

About the National Cancer Center and the National Cancer Center Research Institute

The National Cancer Center Research Institute (NCCRI) was established in 1962 as a department of the National Cancer Center (NCC) in Japan, and has been the nation’s leading cancer research institute for nearly 50 years. It is now internationally recognized for major contributions to various aspects of cancer research worldwide. The mission of the NCCRI is to advance the knowledge of cancer prevention, diagnosis and therapy, toward the ultimate goal of cancer control.